Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children
Search results
13 results
-
-
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages
-
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
-
Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) (DG47)
NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care. We will review this decision if a stakeholder notifies NICE again of the topic
-
COVID-19 rapid guideline: managing COVID-19 (NG191)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily.
-
COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)
This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VITT is a new condition, there is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome.
-
Liposuction for chronic lymphoedema (IPG723)
Evidence-based recommendations on liposuction for chronic lymphoedema in adults. This involves using suction to remove fluid and fat through punctures in the skin
-
Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome (IPG724)
Evidence-based recommendations on personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome
-
Intramedullary distraction for upper limb lengthening (IPG722)
Evidence-based recommendations on intramedullary distraction for upper limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter arm
-
Liposuction for chronic lipoedema (IPG721)
Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat
-
Endoanchoring systems in endovascular aortic aneurysm repair (IPG725)
Evidence-based recommendations on endoanchoring systems in endovascular aortic aneurysm repair. This involves using an anchoring device to hold a stent in place to prevent leaks in an aneurysm repair
-
Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis (IPG726)
Evidence-based recommendations on supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis in adults. This involves replacing a hip using smaller cuts than are used in standard surgery
-
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) (IPG727)
Evidence-based recommendations on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). This involves replacing damaged cartilage with an artificial (synthetic) implant